RCC Patients
Unmet need for adjuvant treatment of renal cell-cancer (RCC) patients post-nephrectomy
- Post-nephrectomy of RCC limited treatment options with an acceptable safety profile available for both non-metastatic and metastatic RCC
- Currently only one adjuvant treatment approved for post-nephrectomy, non-metastatic RCC – Pembrolizumab
- Available treatment option in the adjuvant setting is associated with side effects and a high burden on the patient’s quality of life
- RCC is associated with a high risk of recurrence 5-years post-nephrectomy (approx. 50% of patients) Increasing number of post-5 years recurrence being reported
Solution
VCC-001 is an autologous tumour lysate vaccine based on the individual patient’s tumour cells. Used in Renal Cell Cancer (post-nephrectomy), VCC-001 shows:
- a highly specific immune response with evidence of excellent efficacy
- a very favourable safety and side effects profile (vs. pembrolizumab)
VCC-001 demonstrated a significant survival advantage in Phase III clinical trials:
- Patients with pT3 stage RCC revealed 5- and 10-year OS rates of 71.3% and 53.6% in the study group and 65.4% and
36.2% in the control group (p = 0.022)
In metastatic setting in RCC
General: Principles developed for the autologous tumour vaccine VCC-001 can also be applied or extended to other tumours with unmet medical needs which are amenable to surgery or to other stages of tumours (even including metastases) for which enough tumour material can be obtained by surgery.
COLON AND PANCREAS TUMOR PATIENTS
In extended oncology indications
Principles developed for the autologous tumour vaccine VCC-001 can also be applied or extended to other tumours with unmet medical needs which are amenable to surgery or to other stages of tumours (even including metastases) for which enough tumour material can be obtained by surgery.
